Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain

Fineline Cube Dec 13, 2024

China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) is poised to receive another milestone payment...

Policy / Regulatory

National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs

Fineline Cube Dec 13, 2024

The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were...

Company Medical Device

Grand Pharmaceutical Group Receives NMPA Approval for NOVASYNC HYBRID SYSTM

Fineline Cube Dec 13, 2024

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that it has received marketing...

Company Drug

HuidaGene Therapeutics Launches MUSCLE Study for CRISPR Therapy in Duchenne Muscular Dystrophy

Fineline Cube Dec 13, 2024

Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced the initiation of the MUSCLE study for...

Company Deals

Sunshine Lake Pharma Files for HKEX IPO, Expanding Global Pharmaceutical Reach

Fineline Cube Dec 13, 2024

China-based Sunshine Lake Pharma Co., Ltd has submitted an initial public offering (IPO) filing to...

Company Drug

Transcenta’s LIV-1 ADCs Show Promising Results in Pre-Clinical Breast Cancer Study

Fineline Cube Dec 13, 2024

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) announced updated results from a pre-clinical study...

Company Deals

Mabwell Bioscience Secures Licensing Deal with TABUK Pharmaceutical for MENA Region

Fineline Cube Dec 12, 2024

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has inked a licensing deal with TABUK...

Company Drug

ImmunoTech Biopharm’s CAR-T-19 Earns Breakthrough Therapy Designation for B-ALL Treatment

Fineline Cube Dec 12, 2024

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced receiving...

Company Deals

Grand Pharmaceutical Group Secures Licensing Agreement for CORXEL’s Nasal Sprays in Greater China

Fineline Cube Dec 12, 2024

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced a significant licensing agreement with...

Company Deals

EOSVISION Ltd Secures Series A Funding to Advance Ophthalmic Implant Development

Fineline Cube Dec 12, 2024

Suzhou-based EOSVISION Ltd has reportedly raised close to RMB 100 million (USD 13.78 million) in...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-4729 Peptide Drug

Fineline Cube Dec 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical clearance from...

Company

VIVA Biotech Expands Global Footprint with New Boston Branch

Fineline Cube Dec 12, 2024

China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its...

Company Deals

Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions

Fineline Cube Dec 12, 2024

Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...

Company Deals

Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments

Fineline Cube Dec 12, 2024

Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and...

Company Deals

MDHC Life Technologies Secures Series C++ Funding to Boost Consumer Healthcare and Life Sciences

Fineline Cube Dec 12, 2024

China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds...

Company

Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...

Company Drug

AstraZeneca’s Lynparza Shows Sustained Improvements in OlympiA Phase III Study

Fineline Cube Dec 12, 2024

UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA...

Company Drug

Sanofi Receives FDA Fast-Track Designation for Influenza and COVID-19 Combo Vaccine Candidates

Fineline Cube Dec 12, 2024

Sanofi (NASDAQ: SNY) has announced that it has received Fast-Track Designations from the US Food...

Company Deals

Youjia Biomedical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug

Fineline Cube Dec 12, 2024

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm...

Company Deals

Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the...

Posts pagination

1 … 290 291 292 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.